Madrigal Pharmaceuticals has a first mover advantage in the huge MASH market due to the approval of Rezdiffra. Read whether I ...

We recently published an article titled Billionaire Nicholas J. Pritzker’s 8 Stocks with Huge Upside Potential. In this ...

Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...

Q1 2025 Management View CEO Bill Sibold highlighted the momentum of Rezdiffra’s US launch, reporting $137 million in net sales for Q1 2025, reflecting a 33% increase quarter-over-quarter despite ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

In a new study, Ozempic - a drug sold to help with obesity and diabetes - is attributed to helping this disease.

Rezdiffra sales reached $137 million for the quarter, beating consensus analyst estimates by more than $20 million and ...

It offers Rezdiffra, which is a liver-directed thyroid hormone receptor beta agonist for treating MASH. Following its FDA approval in March 2024, Rezdiffra has shown a strong performance in ...

First-quarter 2025 Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO ...

During the quarter, the company generated total revenues of $137.3 million, entirely from product sales of its metabolic dysfunction-associated steatohepatitis (MASH) drug Rezdiffra (resmetirom ...

CEO Bill Sibold highlighted the momentum of Rezdiffra’s US launch, reporting $137 million in net sales for Q1 2025, reflecting a 33% increase quarter-over-quarter despite typical Q1 industry ...